In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Natural peptide PTH 1-84 (parathyroid hormone) | Natural fragment Teriparatide (PTH 1-34) | |
|---|---|---|---|
| Identity | |||
| Kind | Natural peptide | Natural fragment | |
| Area | Recovery and repair | Recovery and repair | |
| Evidence | |||
| Amount of evidence | 418 | 2,709 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 48 (34 in people) | 209 (168 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 315 more mention it but do not test it | 168 · 15 active30 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Natpara says: “Adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism” No central EU authorisation (EMA).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | PTH 1-84 (parathyroid hormone) | Teriparatide (PTH 1-34) |
|---|---|---|
| Bone and jointMusculoskeletal | 292154138 | 2,2281286 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Forteo says: “The active N-terminal fragment of parathyroid hormone, approved for osteoporosis in selected patients”
| Adverse eventsWhole body | 30264 | 16313726 |
|---|
| PainMusculoskeletal | 11 | 6262 |
|---|
| Electrolyte balanceEndocrine and hormones | 31292 | 3030 |
|---|
| PharmacokineticsPharmacology | 981 | 30273 |
|---|
| Kidney functionKidney and urinary | 1091 | 27243 |
|---|
| Exercise and physical functionMusculoskeletal | 77 | 1818 |
|---|
| Quality of lifeWhole body | 1212 | 1313 |
|---|
| Receptor activity and mechanismKidney and urinary | 11 | 46151516 |
|---|
| Gastrointestinal adverse eventsGastrointestinal | 33 | 1212 |
|---|
| Body weightMetabolic and weight | 312 | 1028 |
|---|
| Body compositionMetabolic and weight | 11 | 541 |
|---|
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | PTH 1-84 (parathyroid hormone) | Teriparatide (PTH 1-34) |
|---|---|---|
| Bone and jointMusculoskeletalCompared as: value in the arm that got the peptide, in % | 7.9% Mean lumbar spine BMD increase at 18 months · PTH(1-84) plus HT Dose studied: 100 microg dailyn not reported2008 | 7.2% Lumbar spine BMD change Dose studied: 20 microg once daily18 monthsn = 4282007 |
| Adverse eventsMusculoskeletalCompared as: value in the arm that got the peptide, in % | 93% Adverse events · rhPTH(1-84) Placebo: 100% Dose studied: 50 μg per day, titrated to 75 μg or 100 μgn = 1342013 |
7.9%
Mean lumbar spine BMD increase at 18 months · PTH(1-84) plus HT
Dose studied: 100 microg dailyn not reported2008
7.2%
Lumbar spine BMD change
Dose studied: 20 microg once daily18 monthsn = 4282007
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | PTH 1-84 (parathyroid hormone) | Teriparatide (PTH 1-34) |
|---|---|---|
| PainMusculoskeletalCompared as: difference from placebo, in % | No comparable result 1 randomized-trial result measure it in another way or another unit. | −31% Relative risk reduction · Shown as a change. The study reports a relative risk reduction of this size. |
86.7% Adverse events Placebo: 86.1% Dose studied: 28.2 μg once weeklyn = 3162014 |
93%
Adverse events · rhPTH(1-84)
Placebo: 100%
Dose studied: 50 μg per day, titrated to 75 μg or 100 μgn = 1342013
86.7%
Adverse events
Placebo: 86.1%
Dose studied: 28.2 μg once weeklyn = 3162014
| Exercise and physical functionMusculoskeletalCompared as: value in the arm that got the peptide, in s | No comparable result 6 randomized-trial results measure it in another way or another unit. | −3.2 to −5.9 s TUG time difference versus risedronate · teriparatide minus risedronate, 6 to 26 weeks Dose studied: 20 μg every day78 weeksn = 1712017 |
|---|
| Electrolyte balanceEndocrine and hormonesCompared as: value in the arm that got the peptide, in % | 53% Response · rhPTH(1-84) Placebo: 2% Dose studied: 50 μg per day, titrated to 75 μg or 100 μg24 weeksn = 1342013 | No comparable result 9 randomized-trial results measure it in another way or another unit. |
|---|
| Body compositionMusculoskeletalCompared as: value in the arm that got the peptide, in % | No comparable result 1 randomized-trial result measure it in another way or another unit. | −3.54% MFF change from baseline · teriparatide group at 6 months 12 monthsn not reported2016 |
|---|
| Gastrointestinal adverse eventsGastrointestinalCompared as: value in the arm that got the peptide, in % | No comparable result 3 randomized-trial results measure it in another way or another unit. | 13% Nausea rate Dose studied: 20 g/day as printed6 monthsn = 1042006 |
|---|
No comparable result
1 randomized-trial result measure it in another way or another unit.
−31%
Relative risk reduction · Shown as a change. The study reports a relative risk reduction of this size.
Dose studied: 20 microgmedian 19 monthsn = 1,0852005
No comparable result
6 randomized-trial results measure it in another way or another unit.
−3.2 to −5.9 s
TUG time difference versus risedronate · teriparatide minus risedronate, 6 to 26 weeks
Dose studied: 20 μg every day78 weeksn = 1712017
53%
Response · rhPTH(1-84)
Placebo: 2%
Dose studied: 50 μg per day, titrated to 75 μg or 100 μg24 weeksn = 1342013
No comparable result
9 randomized-trial results measure it in another way or another unit.
No comparable result
1 randomized-trial result measure it in another way or another unit.
−3.54%
MFF change from baseline · teriparatide group at 6 months
12 monthsn not reported2016
No comparable result
3 randomized-trial results measure it in another way or another unit.
13%
Nausea rate
Dose studied: 20 g/day as printed6 monthsn = 1042006
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 31 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Takeda407 participantsJul 2006 to Aug 2011
Osteoporosis
Shire124 participants18 Dec 2008 to 28 Sept 2011
Hypoparathyroidism
Shire93 participants24 Jan 2018 to 19 May 2022
Hypoparathyroidism
5 more mention it but do not test it. They only measure it or name it in their text.
Top 3 of 168 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Radius Health, Inc.2,463 participantsApr 2011 to Oct 2014
Osteoporosis · Postmenopausal Osteoporosis
Eli Lilly and Company1,366 participantsOct 2012 to Jul 2016
Postmenopausal Osteoporosis
Eli Lilly and Company712 participantsJun 2006 to Jun 2010
Osteoporosis, Postmenopausal · Back Pain · Spinal Fracture
30 more mention it but do not test it. They only measure it or name it in their text.